Lifespan extension therapy:  6-Shogaol, isolated from Zingiber Officinale Roscoe, increases life span via up-regulation of its target gene BubR1, 2/December/2017, 6.27 am

Natural product-based therapy for body weight control, energy homeostasis and TIIDM: Glabridin, an isoflavane isolated from Licorice (Glycyrrhiza glabra),  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 2/December/2017, 6.14 am
December 2, 2017
Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Meranzin hydrate, isolated from Humulus Scandens, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 2/December/2017, 7.41 am
December 2, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy:  6-Shogaol, isolated from Zingiber Officinale Roscoe,  increases life span via up-regulation of its target gene BubR1


What is known? 

6-Shogaol has been shown to possess anti-hyperglycemic property. However, the exact mechanism of action is far from clear.


From research findings to Therapeutic Opportunity: 

This study suggests, for the first time, that 6-Shogaolby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. A therapeutic mix encompassing 6-Shogaol may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. 6-Shogaol functions as a longevity-promoting agent through induction of BuBR1

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “6-Shogaol or its analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 2).

 

 

 

 


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing 6-Shogaol increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy:  6-Shogaol, isolated from Zingiber Officinale Roscoe, increases life span via up-regulation of its target gene BubR1, 2/December/2017, 6.27 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.